<DOC>
	<DOCNO>NCT01312337</DOCNO>
	<brief_summary>The investigator examine efficacy toxicity gefitinib Korean patient EGFR wild tumor diagnose direct sequence test .</brief_summary>
	<brief_title>Iressa EGFR Mutation Negative Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Pathologically proven NSCLC Ineligibile curative treatment ( namely , stage IIIb IV ) History one three prior systemic chemotherapy tumor without active EGFR mutation ( exon 19 deletion , L858R mutation exon 21 ) At least one lesion unidimensionally measurable compute tomography ( RECIST 1.1 ) 18 year old old Performance status ECOG 02 Adequate organ function evidence follow : Absolute neutrophil count &gt; 1.0 x 109/L Platelets &gt; 75 x 109/L Total bilirubin ≤ 1.5 UNL AST and/or ALT &lt; 5 UNL Creatinine clearance ≥ 45mL/min Previous EGFR TKI therapy history Systemic anticancer therapy within previous 3 week Other invasive malignancy within past 2 year except nonmelanoma skin cancer , situ cervix cancer , papillary thyroid cancer Other concurrent illness would preclude study participation ( severe heart disease ) Other concurrent physical condition ( e.g. , infectious disease ) would preclude study participation Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>gefitinib</keyword>
	<keyword>EGFR mutation negative</keyword>
	<keyword>NSCLC</keyword>
</DOC>